<!-- page 1 -->

# **NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE** 

# **HEALTH TECHNOLOGY APPRAISAL PROGRAMME Equality impact assessment – Guidance development** 

# **STA Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction** 

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme. 

## **Final draft guidance** 

(when draft guidance issued) 

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? 

- No further issues were raised. 

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? 

Not applicable. 

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? 

Equality impact assessment for the single technology appraisal of dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction 

Technology appraisals: Guidance development 

1 of 2 




<!-- page 2 -->

Not applicable. 

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE’s obligations to promote equality? 

Not applicable. 

5. Have the committee’s considerations of equality issues been described in the final draft guidance, and, if so, where? 

Yes, Section 3.28 

## **Approved by Associate Director (name):** Jasdeep Hayre 

**Date:** 10 May 2023 

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction 

2 of 2 


